A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Polymyalgia Rheumatica

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Polymyalgia Rheumatica

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 26 May 2017

At a glance

  • Drugs Sirukumab (Primary) ; Prednisone
  • Indications Polymyalgia rheumatica
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 May 2017 Planned End Date changed from 24 Jan 2021 to 26 Aug 2021.
    • 22 May 2017 Planned primary completion date changed from 25 Jan 2020 to 26 Aug 2020.
    • 22 May 2017 Planned initiation date changed from 15 Jun 2017 to 15 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top